WO2017037462A3 - Methods - Google Patents

Methods Download PDF

Info

Publication number
WO2017037462A3
WO2017037462A3 PCT/GB2016/052707 GB2016052707W WO2017037462A3 WO 2017037462 A3 WO2017037462 A3 WO 2017037462A3 GB 2016052707 W GB2016052707 W GB 2016052707W WO 2017037462 A3 WO2017037462 A3 WO 2017037462A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
relates
present
parasites
Prior art date
Application number
PCT/GB2016/052707
Other languages
French (fr)
Other versions
WO2017037462A2 (en
Inventor
Liam Good
Original Assignee
The Royal Veterinary College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Royal Veterinary College filed Critical The Royal Veterinary College
Publication of WO2017037462A2 publication Critical patent/WO2017037462A2/en
Publication of WO2017037462A3 publication Critical patent/WO2017037462A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to compositions and methods for the treatment of obligate or facultative intracellular microorganisms, such as bacteria, fungi or parasites such as protozoan parasites. The present invention also relates to compositions and methods for enhancing immune cell activation, for example macrophage, dendritic cell, monocytes and lymphocyte activation, which is considered to be useful in treating infection, cancer and asthma, for example.
PCT/GB2016/052707 2015-09-03 2016-09-01 Methods WO2017037462A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1515655.7 2015-09-03
GBGB1515655.7A GB201515655D0 (en) 2015-09-03 2015-09-03 Methods

Publications (2)

Publication Number Publication Date
WO2017037462A2 WO2017037462A2 (en) 2017-03-09
WO2017037462A3 true WO2017037462A3 (en) 2017-04-27

Family

ID=54345743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/052707 WO2017037462A2 (en) 2015-09-03 2016-09-01 Methods

Country Status (2)

Country Link
GB (1) GB201515655D0 (en)
WO (1) WO2017037462A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245488A1 (en) * 2018-06-21 2019-12-26 Ucar Dilek Guanidinium derivatives as immunity-inducing agent
CN110051832B (en) * 2019-05-31 2020-11-10 四川农业大学 Heartworm disease vaccine
CN115281146B (en) * 2022-07-08 2023-06-16 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） Construction method of chicken damp-heat syndrome model

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999056755A1 (en) * 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO2013054123A1 (en) * 2011-10-11 2013-04-18 The Royal Veterinary College Methods
WO2014170683A1 (en) * 2013-04-17 2014-10-23 Blueberry Therapeutics Limited Compositions and methods for combating antibacterial resistant bacteria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999056755A1 (en) * 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO2013054123A1 (en) * 2011-10-11 2013-04-18 The Royal Veterinary College Methods
WO2014170683A1 (en) * 2013-04-17 2014-10-23 Blueberry Therapeutics Limited Compositions and methods for combating antibacterial resistant bacteria

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLEN MJ; MORBY AP; WHITE GF: "Cooperativity in the binding of the cationic biocide polyhexamethylene biguanide to nucleic acids", BIOCHEM BIOPHYS RES COMMUN, vol. 318, no. 2, 2004, pages 397 - 404, XP004505394 *
BEHANDLUNG KUTANER LEISHMANIOSE: "Use of Polyhexanide and Nanomedicine Approach for Effective Treatments of Cutaneous Leishmaniasis Die Verwendung von Polyhexaniden und Konzepten der Nanomedizin zur effektiven", 11 May 2016 (2016-05-11), XP055327290, Retrieved from the Internet <URL:https://opus.bibliothek.uni-wuerzburg.de/opus4-wuerzburg/frontdoor/deliver/index/docId/11507/file/Dissertation_Rebuma_Firdessa_Fite.pdf> [retrieved on 20161208] *
KANTARAJA CHINDERA ET AL: "The antimicrobial polymer PHMB enters cells and selectively condenses bacterial chromosomes", SCIENTIFIC REPORTS, vol. 6, 21 March 2016 (2016-03-21), pages 23121, XP055326563, DOI: 10.1038/srep23121 *
LARKIN D F P ET AL: "TREATMENT OF ACANTHAMOEBA KERATITIS WITH POLYHEXAMETHYLENE BIGUANIDE", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 99, no. 2, 1 January 1992 (1992-01-01), pages 185 - 191, XP009025457, ISSN: 0161-6420 *
RACHELLE A REBONG ET AL: "Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 52, no. 10, 1 September 2011 (2011-09-01), United States, pages 7309, XP055326852, Retrieved from the Internet <URL:http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/933248/z7g01011007309.pdf> [retrieved on 20160712] *
REBUMA FIRDESSA ET AL: "Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)", PLOS NEGLECTED TROPICAL DISEASES, vol. 9, no. 10, 2 October 2015 (2015-10-02), US, pages e0004041, XP055326552, ISSN: 1935-2727, DOI: 10.1371/journal.pntd.0004041 *
ZHONGXIN ZHOU ET AL: "Extensive activity of guanidine hydrochloride polymer analogs against antibiotics-resistant clinically isolated strains", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A, CH, vol. 31, no. 8, 30 August 2011 (2011-08-30), pages 1836 - 1843, XP028318730, ISSN: 0928-4931, [retrieved on 20110906], DOI: 10.1016/J.MSEC.2011.08.015 *

Also Published As

Publication number Publication date
WO2017037462A2 (en) 2017-03-09
GB201515655D0 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
EP4293033A3 (en) Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides
MX367417B (en) Methods of screening for microorganisms that impart beneficial properties to plants.
ZA201905488B (en) Tigit- and light-based chimeric proteins
MX2021014709A (en) Methods for increasing red blood cell levels and treating sickle-cell disease.
EP4289910A3 (en) Methods and compositions for wound healing
EP3318564A3 (en) Bicyclic heterocycles as fgfr inhibitors
WO2016033225A3 (en) Antibodies, compositions, and uses
MX2016016881A (en) Antibodies binding axl.
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
WO2014165810A3 (en) Systems and methods to assess microbiomes and treatments thereof
WO2018009512A8 (en) Solids handling in water treatment systems and associated methods
WO2016083798A8 (en) Prevention and treatment of microbial infections
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
WO2015143295A3 (en) Hydrogel toxin-absorbing or binding nanoparticles
EP4218736A3 (en) Compositions comprising 15-hepe
WO2016019270A8 (en) An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
WO2015136287A3 (en) Compositions and methods relating to the treatment of diseases
WO2017037462A3 (en) Methods
WO2014144211A3 (en) Compositions and methods for treating fungal and bacterial pathogens
UA115305C2 (en) Hyr1-derived compositions and methods of treatment using same
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
WO2016060935A3 (en) Compositions and methods of improving the digestibility of animal feed
MX2018010264A (en) Solvent-free formulations of low-melting active substances.
MY190543A (en) Silazane-siloxane random copolymers, their production and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16781521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16781521

Country of ref document: EP

Kind code of ref document: A2